t
Sareum Holdings PLC announced on 8 November 2023 that its CEO, Dr Tim Mitchell, and CSO, Dr John Reader, each exercised options over 95,040 ordinary shares at 30 pence per share. Subsequently, on 7 November 2023, Dr Mitchell sold 72,000 shares and Dr Reader sold 50,426 shares, both at 56.8 pence per share. Following these transactions, Dr Mitchell holds 1,032,561 shares (1.47%) and Dr Reader holds 1,077,111 shares (1.53%) of the Company's issued share capital.
| Date | 8 Nov 2023 |
| Time | 15:03:54 |
| Category | Director/PDMR dealings |
| ID | 8299S |
("Sareum" or the "Company")
Director Dealings
Cambridge, UK, 8 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces the following share transactions carried out by Directors.
As announced on 2 November 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each in the Company (the "Options Exercise"), at an exercise price of 30 pence per ordinary share.
Of those shares received pursuant to the Options Exercise, Dr Mitchell and Dr Reader have retained 23,040 and 44,614 ordinary shares, respectively, following the sale of 72,000 and 50,426 ordinary shares, respectively, at a price of 56.8 pence per ordinary share (the "Share Sales"). The Share Sales were undertaken partly in order to compensate for the cost and tax liabilities arising from the Options Exercise.
Following the Options Exercise and Share Sales, Dr Mitchell's and Dr Reader's resultant interests in the Company will be as follows:
|
Director/ |
Number of shares purchased pursuant to the Options Exercise |
Number of shares sold pursuant to Sale Shares |
Sale price |
Resultant total number of ordinary shares held in the Company |
Percentage of issued share capital |
|
Tim Mitchell (1) |
95,040 |
72,000 |
56.8p |
1,032,561 |
1.47% |
|
John Reader (2) |
95,040 |
50,426 |
56.8p |
1,077,111 |
1.53% |
(1) - Included within Tim Mitchell's total holding are 200,000 ordinary shares held by his spouse.
(2) - Included withing John Reader's total holding are 66,666 ordinary shares held by his spouse.
For further information, please contact:
|
Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations
|
01223 497700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm
|
020 7418 8900 |
|
Hybridan LLP (Joint Corporate Broker) Claire Noyce
ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki
|
020 3764 2341
020 3709 5700 |
PDMR Notification Forms
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Tim Mitchell |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chief Executive Officer |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
SAREUM HOLDINGS PLC |
||||
|
b) |
LEI |
213800PKERN2DY8FFM72 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares of 1.25p each in the share capital of Sareum Holdings plc |
||||
|
Identification code |
ISIN for Ordinary Shares: GB00B02RFS12 |
|||||
|
b) |
Nature of the Transaction |
Sale of ordinary shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
|
||||
|
e) |
Date of the transaction |
7 November 2023 |
||||
|
f) |
Place of the transaction |
London Stock Exchange (AIM) |
||||
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
John Reader |
||||
|
2. |
Reason for the Notification |
|||||
|
a) |
Position/status |
Chief Scientific Officer |
||||
|
b) |
Initial notification/amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
SAREUM HOLDINGS PLC |
||||
|
b) |
LEI |
213800PKERN2DY8FFM72 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc |
||||
|
Identification code |
ISIN for Ordinary Shares: GB00B02RFS12 |
|||||
|
b) |
Nature of the Transaction |
Sale of ordinary shares |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
|
||||
|
e) |
Date of the transaction |
7 November 2023 |
||||
|
f) |
Place of the transaction |
London Stock Exchange (AIM) |
||||
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -